5 to efficiently activate naive T cells correlates with their property to perform different functions at distinct sites. Immature DC in peripheral tissues respond to inflammatory stimuli and microbial products, mature subsequently and home to lymphoid organs. In contrast to immature peripheral DC, mature DC in lymphoid tissues express high levels of MHC class II (MHC II) and costimulatory molecules, allowing efficient priming of naive T cells (1). Many lines of evidence indicate that, in contrast to their mature counterparts, immature DC can tolerize T cells; this was demonstrated by direct DC-targeting of Ag via DEC-205 (2), cross-presentation induced deletion of Ag-specific CD8 ϩ T cells (3), as well as inducible DC-specific expression of Ag in vivo (4).
T he unique ability of dendritic cells (DC) 5 to efficiently activate naive T cells correlates with their property to perform different functions at distinct sites. Immature DC in peripheral tissues respond to inflammatory stimuli and microbial products, mature subsequently and home to lymphoid organs. In contrast to immature peripheral DC, mature DC in lymphoid tissues express high levels of MHC class II (MHC II) and costimulatory molecules, allowing efficient priming of naive T cells (1) . Many lines of evidence indicate that, in contrast to their mature counterparts, immature DC can tolerize T cells; this was demonstrated by direct DC-targeting of Ag via DEC-205 (2), cross-presentation induced deletion of Ag-specific CD8 ϩ T cells (3) , as well as inducible DC-specific expression of Ag in vivo (4) .
However, analysis of spleen sections showed that the majority of DC of naive mice are of an immature phenotype and can still be driven into further maturation (3, 5, 6) . This raised the question about roles of these immature DC in lymphoid organs and fostered the attractive hypothesis of immature DC guarantying maintenance of tolerance to peripheral self-Ags (1, 5, 7) . Data showing acquisition, processing, and presentation of parietal cell- (8) or pancreatic ␤-cell-derived self-Ags (9) support this possibility. However, other studies showed that "being immature" was not sufficient for DC to exert tolerogenic functions, because only phenotypically mature DC could induce cross-tolerance of CD8 ϩ T cells (10) , initiate IL-10-mediated tolerance in a murine model of allergic asthma (11) , or induce regulatory T cells, which suppress diabetes in NOD mice (12) . Expression of the costimulatory molecules CD80 and/or CD86 on mature DC was also a prerequisite for optimal expansion of suppressive CD4 ϩ CD25 ϩ T cells (13) . Furthermore, injection of semimature, but not completely immature DC loaded with encephalitogenic myelin oligodendrocyte glycoprotein (MOG) self-peptide induced IL-10-producing CD4 ϩ T cells and protected mice from subsequent induction of experimental autoimmune encephalomyelitis (EAE) with the same peptide (14) . This led to a new concept suggesting that semimature DCthe in vitro-created counterparts of naturally occurring steady-state DC in lymphoid organs-can tolerize naive CD4 T cells (15) .
In the present study, we investigated whether this concept is applicable also 1) to CD4 T cells specific for foreign Ag and 2) to tolerize CD8 T cells directly or 3) to tolerize CD8 T cells via IL-10-producing bystander CD4 T cells. Here we demonstrate that the same semimature DC loaded with several different antigenic peptides simultaneously induce MHC II-restricted IL-10-producing T cells responsible for protective tolerance to MHC II-restricted Ag as well as immunity toward class I-restricted Ag. Our data indicate that the same semimature DC can induce simultaneously tolerance and immunity, depending on the type of T cell responding to the presented Ag. buffer (0.15 M NH 4 Cl, 1 mM KHCO 3 , 0.1 mM Na 2 EDTA, pH 7.4) for 4 min at room temperature. 
Dendritic cells
DC were generated from C57BL/6 bone marrow progenitors using GM-CSF as described previously (19) . On day 8 of culture, DC were tested for purity by staining with anti-CD11c and anti-MHC II. Purity of DC was routinely around 80%. DC were pulsed for 4 h in complete medium (RPMI 1640 supplemented with 5% FCS, 50 mM 2-ME, and 1% penicillin/strepomycin) with 20 g/ml OVA 257-264 , 10 M OVA 323-339, 10 M MOG (Neosystem) or mixtures of these. TNF-␣ (500 U/ml) and LPS (1 g/ml) were added for 4 h while DC were loaded with peptide. The cells were then washed extensively in PBS, and 2.5-4 ϫ 10 6 DC were injected i.v. into the lateral tail vein of recipient mice.
T cell restimulation and ELISA
Supernatants from spleen cell restimulations were collected after 96 h, and cytokines produced from spleen cells were detected using ELISA kits for IL-10 and IFN-␥ (BD Pharmingen).
Immunostaining and flow cytometry
mAbs used in this study were anti-V␤5.1/5.2-FITC (MR9-4), anti-V␣2-biotin (B20.1), anti-CD8-PerCP (53-6.7), and streptavidin-PerCP. All Abs were purchased from BD Pharmingen. A FACSCalibur flow cytometer and CellQuest Software from BD Biosciences were used to collect and analyze the data. Nonviable cells were excluded using forward and side scatter electronic gating.
Induction of EAE and diabetes
MOG peptide (Biotrend Chemikalien) was used to induce EAE in C57BL/6 mice as described before (14) . Briefly, C57BL/6 mice were injected s.c. with 50 g of MOG peptide in 50 l of PBS emulsified in 50 l of CFA that was further enriched with 10 mg/ml Mycobacterium tuberculosis (H37Ra; Difco/BD Pharmingen). In addition 200 ng of Pertussis toxin (List/Quadratech) were injected i.p. at days 0 and 2. Mice were observed daily for clinical signs of disease. Mice were scored according to their clinical severity of disease as follows: grade 0, no abnormality; grade 1, limp tail; grade 2, limp tail and hind limb weakness (waddling gait); grade 3, partial hind limb paralysis; grade 4, complete hind limb paralysis; and grade 5, moribund. The data are plotted as the mean daily clinical score for all animals in a particular treatment group.
Glucose levels in the urine were checked every day by glucose test strips (Diabur-Test 5000) from Roche Diagnostics. Mice were considered diabetic when glucose concentration was Ͼ5.5 mmol/L.
In vivo CTL assay
This assay was performed as described before (20) . Syngeneic C57BL/6 spleen and lymph node cells were depleted of erythrocytes by osmotic lysis. Cells were washed and split into two populations. 
Results

Semimature DC can induce IL-10-producing CD4 T cells specific for self and foreign Ag
Semimature DC are indistinguishable from fully mature DC according to surface expression of typical DC maturation markers. However, they lack the ability to produce cytokines and, therefore, induce IL-10-mediated regulatory responses rather than IFN-␥-producing T effector cells. To investigate tolerance induction by TNF-␣-treated semimature DC, we incubated DC from GM-CSF bone-marrow cultures with either LPS or TNF-␣ as described previously (14) . Both, LPS and TNF-␣-treated DC were similarly mature according to surface expression of MHC II, CD80, CD86, CD25, MHC class I (MHC I), and CD40 (data not shown). However, as we reported previously (14) , in contrast to LPS-DC, semimature TNF-DC did not produce IL-6, IL-12p40, or IL-12p70 (data not shown) and were able to prevent EAE via an IL-10-dependent mechanism, when loaded with MOG 35-55 -peptide and injected into C57BL/6 mice (Ref. 14, data not shown, and see Fig. 3 ).
To further assess the immunostimulatory capacities of the differentially matured DC, we immunized mice three times with LPSor TNF-DC loaded with either the class II-restricted MOG or OVA 323-339 peptide. Restimulation of T cells with the relevant peptide showed in general weaker proliferative T cell responses in those mice injected with TNF-DC as compared with fully mature LPS-DC (Fig. 1A) . Also the produced cytokine-patterns were different: while T cells from LPS-DC immunized mice produced both IFN-␥ (Fig. 1B) as well as IL-10 ( Fig. 1C ) in response to antigenic peptide, the TNF-DC pretreatment lead to strongly diminished IFN-␥ production (Fig. 1B) . Therefore, TNF-DC induced Ag-specific IL-10-producing T cells specific for MOG self-Ag (as described previously (14)), but also for the foreign model-Ag OVA.
Semimature DC elicit diabetes in RIP-OVA low mice
To analyze if semimature DC might be used to either directly or indirectly tolerize CD8 ϩ T cells and have therapeutic effects in CD8 ϩ T cell-mediated autoimmune diseases, we usedthe OT-I adoptive transfer model to induce diabetes in RIP-OVA low mice. Transgenic RIP-OVA low mice, which express OVA as model autoantigen under control of the rat insulin promoter, are tolerant to OVA, which is expressed on the ␤ cells of the pancreatic islets (16) . Upon transfer into these hosts, naive "autoreactive" OVAspecific CD8
ϩ CTL from TCR-transgenic OT-I mice, are ignorant to their specific Ag due to low amounts of OVA expression in RIP-OVA low recipients (16, (21) (22) (23) . However, when OT-I T cells become activated in vivo, they expand and destroy the OVA-expressing pancreas inducing diabetes as measured by high urine glucose levels (16, (21) (22) (23) . To examine the tolerizing capacity of semimature DC in this system, OVA 257-264 -pulsed TNF-DC or LPS-DC were injected into RIP-OVA low mice reconstituted with 1 ϫ 10 6 OT-I cells. To monitor T cell expansion, blood was analyzed and the percentage of OT-I T cells determined by flow cytometry (Fig. 2A) . After i.v. immunization OT-I T cells expanded to over 70% of CD8 ϩ PBL (Fig. 2A) . The kinetic of OT-I expansion induced by mature or semimature DC was similar in all mice, peaked at day 4 postinfection (Fig. 2A) and was comparable, when PBL ( Fig. 2A ) and spleens (data not shown) were analyzed. However, because T cell expansion not only accompanies activation but also tolerization of T cells (24, 25) , we determined diabetes induction as a sign for CTL activation in vivo. Although all mice treated with mature or semimature DC were clinically scored as diabetic (Fig. 2B, left panel) , the urine glucose levels in the group treated with TNF-DC was in average 2-to 3-fold lower (Fig.  2B, left panel) . In addition, while LPS-DC-treated animals did not clinically improve, the TNF-DC-treated mice fully recovered from diabetes after 27 days (Fig. 2B, left panel) . However, after complete recovery of the animals vaccinated with TNF-DC (day 27, Fig. 2B, left panel) , a second immunization of the recovered animals with OVA 257-264 (100 g in CFA s.c.) induced strong diabetes with no recovery and, therefore, excluded the possibility that CD8 T cell tolerance induction by TNF-DC could be accompanied by transient acquisition of cytolytic function (Fig. 2C ). Taken together, these data suggest that semimature TNF-DC have no direct tolerogenic capacity toward CD8 ϩ T cells, but rather activate them to effector killer cells. However, this activation was weaker as compared with CTL induced by fully mature LPS-DC.
It has previously been shown, that TNF-DC can mediate tolerance via IL-10-producing Ag-specific CD4 regulatory T cells (14) . Because RIP-OVA low mice are tolerant for OVA and their repertoire of T cells specific for OVA is either purged or tolerized (16, 21, 22) , we studied whether provision of an exogenous source of OVA-specific CD4 Th cells from TCR-transgenic OT-II mice might overcome the absence of tolerance induction by TNF-DC. Therefore, we cotransferred both OT-I and OT-II cells into RIP-OVA low mice and treated them with LPS-DC or TNF-DC pulsed simultaneously with both OVA 257-264 and OVA 323-339 . However, also in the presence of CD4 ϩ OT-II cells and their specific peptide on DC, mice from both experimental groups developed diabetes (Fig. 2B, right panel) . Moreover, mice immunized with OVA 257-264 / OVA 323-339 -loaded TNF-DC did not recover from diabetes, and their urine glucose levels were similarly elevated as compared with mice immunized with fully mature DC (Fig. 2B, right panel) . So far our data indicate that TNF-DC are neither capable without (Fig.  2B) or with (Fig. 2B ) the help of Ag-specific CD4 cells to tolerize OVA-specific OT-I CD8 T cells and rather activate CD8 cells to become cytotoxic effector cells.
Semimature DC induce CTL function in C57BL/6 mice and simultaneously protect from CD4 T cell-mediated EAE
To exclude that absence of tolerance induction by TNF-DC was due to the transgenic nature of OT-I or OT-II T cells, or their artificially elevated precursor frequencies, we next compared polyclonal CTL responses induced by mature and semimature DC. To analyze the cytotoxic activity induced by the different DC, we performed "in vivo killer assays" (20) in normal C57BL/6 mice. DC-treated mice were injected with a 1:1 mixture of differently CFSE-labeled spleen cell targets, either pulsed with OVA 257-264 -peptide (CFSE high) or unpulsed (CFSE low) (Fig. 3A) . CTLs generated by immunization of the mice with mature OVA 257-264 -loaded DC, selectively killed the peptide-loaded (CFSE high) target cell population (Fig. 3A) within a few hours, allowing calculation of specific lysis (20) . As shown in Fig. 3A , killing of injected OVA 257-264 -pulsed spleen cells was not statistically different in mice treated with OVA 257-264 -loaded LPS-or TNF-DC. Furthermore, when CD4 T cell epitopes of MOG or OVA or both were provided together with the OVA 257-264 MHC I epitope on DC as well as on the targets, similar specific killing was observed in each group (Fig. 3A) . These results indicate, that neither OVA-nor MOG-specific IL-10-producing CD4 T cells (Fig. 1) suppressed the CD8 T cell responses as bystanders.
We next analyzed cytokine production of CD8 T cells induced by mature or semimature DC. Restimulated splenocytes from mice treated with OVA 257-264 -pulsed LPS-DC produced mainly IFN-␥, but no or little IL-10, while semimature TNF-DC did not elicit any significant cytokine responses at all (Fig. 3B) . The absence of IFN-␥ secretion by CD8 T cells from mice immunized with TNF-DC (Fig. 3B ) in contrast to those treated with fully mature DC indicates incomplete induction of CTL responses in vivo. However, these IFN-␥ negative CD8 T cells do show cytolytic functions (Figs. 2B and 3A) .
To proof that TNF-DC loaded with either MOG or both OVA 257-264 and MOG were similarly tolerogenic for MOGspecific T cells and able to protect mice from EAE, we induced EAE in mice treated as in Fig. 3A . As published before (14) , immunization with semimature MOG 35-55 -loaded DC protected C57BL/6 mice from EAE, while mice without DC-treatment or injected with mature MOG 35-55 -pulsed LPS-DC developed severe EAE (Fig. 3C, MOG) . However, the same semimature DC loaded with both, MOG and OVA [257] [258] [259] [260] [261] [262] [263] [264] , that induced specific CTLs against the MHC I peptide OVA [257] [258] [259] [260] [261] [262] [263] [264] (Fig. 3A) protected mice from MOG-induced EAE (Fig. 3C) . These data suggest that the same semimature DC, which induce MOG-specific IL-10-producing CD4 (regulatory) T cells triggers simultaneously cytotoxic effector T cells, which kill targets (Fig. 3A) in absence of IFN-␥ production. The latter were not inhibited by bystander regulatory T cells triggered most likely in their vicinity, because efficient cytolytic activity was induced also by double-, and triple-loaded semimature DC (Fig. 3B) .
Taken together, these data suggest that the tolerizing capacity of semimature DC is restricted to Ag-specific CD4 T cells, but ineffective to suppress TCR transgenic (Fig. 2) as well as polyclonal CD8 T cells (Fig. 3 ) specific for OVA.
Discussion
In vivo counterparts to the in vitro-generated TNF-DC used in this study could be DC in the lymphatics, which migrate from nonlymphoid organs to peripheral lymph nodes, transporting apoptotic cells (26) or tissue (self-)Ag (8, 9, 27) . In the lymph node and spleen, these migrated DC are crucial to induce peripheral tolerance (2, 28, 29) . The semimature stage of these "steady-state" DC might be attributed to lack of activation by pathogens via TLR ligation leading to phenotypically mature DC that do not produce IL-12 (data not shown and Ref. 14). However, also active suppression of IL-12 production in mature DC has been described for helminth Ag, such as schistosome egg Ag (30) and induction of a general block of DC-maturation was demonstrated for secreted Ag from M. tuberculosis (31) . Therefore, several arguments emerged, which support the existence of semimature DC in vivo induced either by lack of appropriate signals or pathogen-induced maturation blockade. It is therefore important to understand the functions of such semimature DC in more detail.
In vitro-cultured TNF-␣-treated semimature DC loaded with MOG peptide induce MOG -specific tolerance and protect C57BL/6 mice from MOG 35-55 -induced EAE (Ref. 14 and Fig. 3C ). As experiments with semimature DC from IL-10 Ϫ/Ϫ mice showed, DC do not have to produce IL-10 themselves to excert tolerogenic capacity (14) . This is in contrast to IL-10-producing DC protecting from EAE (32, 33) or inducing mucosal tolerance (11) in other studies. Similar to immature human DC (34, 35 ) the mechanism of MOG-tolerance induction by semimature DC was revealed to be dependent on IL-10-producing regulatory T cells (14) , a mechanism that has been demonstrated to act also through bystander suppression (36, 37) .
Therefore, we investigated the tolerizing capacity of semimature DC to CD4 T cells specific for nonself Ag and CD8 ϩ T cells in addition to the described MOG-self Ag specific CD4 T cell response (14) . We show that semimature DC induce a similar IL-10-biased cytokine pattern in foreign Ag (OVA)-specific CD4 T cells as observed for self-Ag-specific MOG T cells (Fig. 1) .
When adoptively transferred transgenic OT-I or endogenous polyclonal CD8
ϩ T cells were exposed to MHC I specific peptideloaded semimature DC in vivo, T cell expansion (Fig. 2) as well as cytotoxic T cell effector functions (Figs. 2 and 3) were induced. Also the addition of exogenous IL-10-producing CD4 T cells (Fig.  2) and simultaneous presentation of corresponding CD4 peptides by semimature DC (Figs. 2 and 3) did not lead to tolerance induction, but rather enhanced CD8 T cell responses (Fig. 2) . The magnitude of CD8 responses (Fig. 2 ) was lower and CD8 cytokine production (Fig. 3) absent, when the responses were initiated by semimature DC. This phenomenon could 1) be due to absent IL-12 production by DC (Ref. 14 and data not shown) and 2) be overcome by addition of exogenous Ag-specific CD4 ϩ T cell help (Fig.  2) . Similar to another report (10) , where presence of CD4 ϩ T cells altered tolerogenic DC in activating DC, we detected an enhancement of CD8 T cell immunity (Fig. 2) . When DC were simultaneously loaded with the tolerogenic MOG peptide as well as OVA peptides, the same DC induced tolerance for MOG (Fig.  3C ), but immunity for OVA by triggering OVA-specific CD8 ϩ cytotoxic T cell responses (Figs. 2B and 3A) . This latter experiment indicated that IL-10-producing MOG-or OVA-peptide specific regulatory CD4 T cells were insufficient to exert bystander suppression on CD8 T cells, neither during priming by the same double-or triple (MOG/OVA)-loaded DC, nor at the level of recognition of (MOG/OVA)-presenting targets (Fig. 3) . Data from other experimental systems have suggested that bystander suppression is mediated through IL-10, TGF-␤ or cell-cell contacts (36, 37) . Hypothetically the semimature DC induce or expand IL-10-producing MOG-specific regulatory T cells, which then may suppress autoreactive clones of similar specificities at other sites and at later time points (for example, when the disease is induced). However, it is not clear yet whether CD8 T cells have similar requirements for tolerization like MOG-specific EAE-inducing CD4 T cells. Therefore, it is possible that semimature DC cannot tolerize CD8 T cells efficiently, suggesting differential requirements for CD4 and CD8 T cells. Another potential reason for the observed differences between CD4 and CD8 T cells might be the differential loading efficiency of TNF-DC with MHC I vs II peptides. In general, much more peptide is required to trigger the effector function of CD4 T cells when compared with CD8 T cells, and this could also account for the phenotype described in this study. Although we tried in our experiments to work under saturating conditions for peptide loading, an adequate comparison of MHC I-and II-induced responses seems to be impossible.
The OVA-specific CTL induced by TNF-DC were unable to produce IFN-␥, which is an indication that their activation was not complete (Fig. 3B) . Therefore, together with the data from Fig. 2 , one could speculate that a reason for this observed cytotoxic activity could be the relatively low threshold signals needed to trigger CTL-activity: one or few specific TCR/peptide-MHC interactions are necessary to induce the cytolytic machinery (38, 39) and even partially activated CD8 T cells can gain cytoloytic activity (40, 41) . In earlier studies the phenomenon of cytotoxic activity in absence of cytokine production has been called "split anergy" (42, 43) . Taken together, "CTL" induced by IL-12 Ϫ TNF-DC might be severely impaired in their tumor-(44) and virus-clearing (45) efficiencies, but are definitely not tolerized.
Overall our results suggest that one DC can exert different functions on CD4 and CD8 T cells simultaneously: induction of CD4 T cell tolerance as well as CD8 T cell immunity. However, it remains an open question, if such an artificially enforced experimental situation of a double-peptide-loaded semimature DC is at all existing in vivo. A potential restriction for such a scenario could be the intrinsically different Ag uptake, processing, and presentation capacities of distinct DC-subsets; i.v. injected soluble OVA has been shown to be taken up by splenic DC, which after isolation, markedly differed in their capacity to present the processed OVA. Although the CD8␣ ϩ DC predominantly cross-presented OVA to CD8 T cells but showed little stimulation of CD4 T cells, the contrary was observed for the CD8␣ Ϫ DC subsets which readily presented OVA in an MHC II-restricted fashion but poorly on MHC I molecules (46) .
However, other examples for a segregation of function within one APC have been published before. It was shown that DC copulsed with microbial and helminth Ag were able to prime Th1 responses for the microbial Ag as well as Th2 responses for the helminth Ag (47) . Therefore, there is increasing evidence for differential handling of different Ag within the same APC. As a consequence, subsequent induction of qualitatively different immune responses by one and the same DC could appear.
Specifically relevant for the question of maintenance of tolerance to apoptotic self-material were recent findings demonstrating that apoptotic (self-) material and bacterial Ag are handled by discrete intracellular phagosomal maturation and processing pathways in APC, depending on their respective TLR signaling (48) . Such a signaling by bacterial material induced phagocytosis and processing pathways, which were independently regulated from constitutive pathways for apoptotic material (48) . It seems an attractive hypothesis that DC are equipped with endogenous control mechanisms, allowing them to integrate processing and presentation requirements for different Ags to avoid in vivo situations like the one induced by unphysiological external peptide loading in our study.
Although the physiological occurrence of such a simultaneous induction of tolerance and immunity in vivo seems unlikely, our findings have implications for in vitro-loaded DC as they are currently used for human cancer immunotherapy. When patient-derived DC are loaded with peptides on MHC I and/or II molecules but are improperly matured, the possibility of simultaneous CD4 tolerance and only partial CD8 immunity should be taken into consideration. In addition, these data indicate that CD4 and CD8 T cells have different activation requirements from the side of the APC. Althoughthe semimature state of the presenting DC is suboptimal and therefore still tolerogenic for CD4 T cells, the costimulatory and cytokine equipment is sufficient to induce CTL activity, however, with reduced/absent IFN-␥ production.
